Somagenetix

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

No changes recorded yet. Missing observations do not mean the company has not changed.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

1. Seen November 2026 · 1 capture · latest observed messagingCURING GENETIC DISORDERS

   Ex-vivo gene therapy for phagocyte disorders. Somagenetix develops lentiviral HSC programs, starting with CGD—advancing safe, durable, one-time treatments.

   This wording observed 6 November 2026.

   current websiteHistorical capture not publicly available
2. Seen January 2026 · 1 captureSomagenetix | Ex-vivo Gene Therapy for CGD & Phagocyte Disorders

   Ex-vivo gene therapy for phagocyte disorders. Somagenetix develops lentiviral HSC programs, starting with CGD—advancing safe, durable, one-time treatments.

   This wording observed 13 January 2026.

   archived page

Companies in the same space

Competitors picked by an AI model from the funded startups with the most similar descriptions, judged on those descriptions only. A reading, not a verified market map.

• Orchard Therapeutics orchard-tx.comDirect competitorBoth develop ex vivo autologous HSC gene therapies for rare inherited disorders.
• Rocket Pharmaceuticals rocketpharma.comPartial overlapBoth develop lentiviral and other gene therapies targeting rare inherited diseases.
• Garuda Therapeutics garudatx.comPartial overlapBoth focus on hematopoietic stem cell–based therapies for rare blood and immune disorders.
• Cellogen Therapeutics cellogentherapeutics.comPartial overlapBoth work on gene therapy approaches for blood-related disorders using engineered cells.
• Genespire genespire.comPartial overlapBoth develop lentiviral-based gene therapies for rare genetic diseases, though via different delivery routes.